Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

University of Cologne65 enrolled

Overview

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hodgkin´s Lymphoma

Interventions

CyclophosphamideDRUG

AdramycinDRUG

ProcarbacineDRUG

PrednisoneDRUG

Eligibility

Sex: ALLMin age: 61 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hodgkin´s lymphoma (histologically proven) * CS (PS) I and II with one of the risk factors a-d 1. bulky mediastinal mass (\> 1/3 maximum transverse thorax diameter) 2. extranodal involvement 3. ESR \> 50 (A), \> 30 (B-symptoms) 4. 3 or more lymph node areas involved * CS (PS) III and IV * Written informed consent Exclusion Criteria: * Leukocytes \<3000/microl * Platelets \<100000/microl * Hodgkin´s Disease as "composite lymphoma" * Activity index (WHO) \< grade 2

Locations (1)

University of Cologne

Cologne, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.